The DOI matches its Crossref record; 210 of the 210 references it cites were found in a registry or an index.
Mechanisms of Resistance and Current Treatment Options for Glioblastoma Multiforme (GBM)
Open accessAbstract
Glioblastoma multiforme (GBM) is a highly aggressive form of brain cancer that is difficult to treat due to its resistance to both radiation and chemotherapy. This resistance is largely due to the unique biology of GBM cells, which can evade the effects of conventional treatments through mechanisms such as increased resistance to cell death and rapid regeneration of cancerous cells. Additionally, the blood–brain barrier makes it difficult for chemotherapy drugs to reach GBM cells, leading to reduced effectiveness. Despite these challenges, there are several treatment options available for GBM. The standard of care for newly diagnosed GBM patients involves surgical resection followed by concurrent chemoradiotherapy and adjuvant chemotherapy. Emerging treatments include immunotherapy, such as checkpoint inhibitors, and targeted therapies, such as bevacizumab, that attempt to attack specific vulnerabilities in GBM cells. Another promising approach is the use of tumor-treating fields, a type of electric field therapy that has been shown to slow the growth of GBM cells. Clinical trials are ongoing to evaluate the safety and efficacy of these and other innovative treatments for GBM, intending to improve with outcomes for patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,668
Identification of human brain tumour initiating cells
Singh, S. K., Hawkins, C., Clarke, I. D., Squire, J. A., Bayani, J., Hide, T., Henkelman, R. M., Cusimano, M. D., & Dirks, P. B. (2004) · Nature · doi:10.1038/nature03128 · Cited by 7,433
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,379
Astrocyte-endothelial interactions at the blood-brain barrier
Abbott, N. J., Rönnbäck, L., & Hansson, E. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1824 · Cited by 5,595
Structure and function of the blood–brain barrier
Abbott, N. J., Patabendige, A. A. K., Dolman, D. E. M., Yusof, S. R., & Begley, D. J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.030 · Cited by 5,185
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
Grauer, O. M., Wesseling, P., & Adema, G. J. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00315.x · Cited by 4,007
Cancer regression in patients after transfer of genetically engineered lymphocytes
Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603
Management of glioblastoma: State of the art and future directions
Tan, A. C., Ashley, D. M., López, G. Y., Malinzak, M., Friedman, H. S., & Khasraw, M. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21613 · Cited by 1,972
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Sugar for the brain: the role of glucose in physiological and pathological brain function
Mergenthaler, P., Lindauer, U., Dienel, G. A., & Meisel, A. (2013) · Trends in Neurosciences · doi:10.1016/j.tins.2013.07.001 · Cited by 1,612
Stem Cell–like Glioma Cells Promote Tumor Angiogenesis through Vascular Endothelial Growth Factor
Bao, S., Wu, Q., Sathornsumetee, S., Hao, Y., Li, Z., Hjelmeland, A. B., Shi, Q., McLendon, R. E., Bigner, D. D., & Rich, J. N. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1010 · Cited by 1,345
Hanif, F., Muzaffar, K., Perveen, K., Malhi, S. M., & Sımjee, S. U. (2017) · PubMed · doi:10.22034/apjcp.2017.18.1.3 · Cited by 1,231
The protein tyrosine kinase family of the human genome
Robinson, D. R., Wu, Y.-M., & Lin, S.-F. (2000) · Oncogene · doi:10.1038/sj.onc.1203957 · Cited by 1,167
Weller, M., Wick, W., Aldape, K., Brada, M., Berger, M., Pfister, S. M., Nishikawa, R., Rosenthal, M., Wen, P. Y., Stupp, R., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.17 · Cited by 1,124
Molecular targeted therapy: Treating cancer with specificity
Lee, Y. T., Tan, Y. J., & Oon, C. E. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.07.034 · Cited by 1,067
Kircher, M. F., de la Zerda, A., Jokerst, J. V., Zavaleta, C. L., Kempen, P. J., Mittra, E., Pitter, K., Huang, R., Campos, C., Habte, F., et al. (2012) · Nature Medicine · doi:10.1038/nm.2721 · Cited by 1,064
Stupp, R., Hegi, M. E., Gorlia, T., Erridge, S. C., Perry, J., Hong, Y.-K., Aldape, K. D., Lhermitte, B., Pietsch, T., Grujicic, D., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70379-1 · Cited by 1,052
A Review of Cancer Immunotherapy: From the Past, to the Present, to the Future
Esfahani, K., Roudaia, L., Buhlaiga, N., Del Rincon, S. V., Papneja, N., & Miller, W. H. (2020) · Current Oncology · doi:10.3747/co.27.5223 · Cited by 954
Glioblastoma multiforme: Pathogenesis and treatment
Alifieris, C., & Trafalis, D. T. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.05.005 · Cited by 820
Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance
Wu, W., Klockow, J. L., Zhang, M., Lafortune, F., Chang, E., Jin, L., Wu, Y., & Daldrup-Link, H. E. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105780 · Cited by 805
Glioblastoma: pathology, molecular mechanisms and markers
Aldape, K., Zadeh, G., Mansouri, S., Reifenberger, G., & von Deimling, A. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1432-1 · Cited by 735
Phase II Trial of Gefitinib in Recurrent Glioblastoma
Rich, J. N., Reardon, D. A., Peery, T., Dowell, J. M., Quinn, J. A., Penne, K. L., Wikstrand, C. J., Van Duyn, L. B., Dancey, J. E., McLendon, R. E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.110 · Cited by 734
Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors
Roybal, K. T., Williams, J. Z., Morsut, L., Rupp, L. J., Kolinko, I., Choe, J. H., Walker, W. J., McNally, K. A., & Lim, W. A. (2016) · Cell · doi:10.1016/j.cell.2016.09.011 · Cited by 721
The brain tumor microenvironment
Charles, N. A., Holland, E. C., Gilbertson, R., Glass, R., & Kettenmann, H. (2011) · Glia · doi:10.1002/glia.21136 · Cited by 718
FDA Drug Approval Summary: Bevacizumab (Avastin®) as Treatment of Recurrent Glioblastoma Multiforme
Cohen, M. H., Shen, Y. L., Keegan, P., & Pazdur, R. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0121 · Cited by 655
Engineering CAR-T Cells for Next-Generation Cancer Therapy
Hong, M., Clubb, J. D., & Chen, Y. Y. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.07.005 · Cited by 639
Epidemiology of Glioblastoma Multiforme–Literature Review
Grochans, S., Cybulska, A. M., Simińska, D., Korbecki, J., Kojder, K., Chlubek, D., & Baranowska-Bosiacka, I. (2022) · Cancers · doi:10.3390/cancers14102412 · Cited by 630
The dynamic blood–brain barrier
Keaney, J., & Campbell, M. (2015) · The FEBS Journal · doi:10.1111/febs.13412 · Cited by 616
Batchelor, T. T., Mulholland, P., Neyns, B., Nabors, L. B., Campone, M., Wick, A., Mason, W., Mikkelsen, T., Phuphanich, S., Ashby, L. S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.2464 · Cited by 614
Recent advancements in liposome technology
Filipczak, N., Pan, J., Yalamarty, S. S. K., & Torchilin, V. P. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.022 · Cited by 592
Self-citationCAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity
Choi, B. D., Yu, X., Castano, A. P., Bouffard, A. A., Schmidts, A., Larson, R. C., Bailey, S. R., Boroughs, A. C., Frigault, M. J., Leick, M. B., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0192-1 · Cited by 571
Dirkse, A., Golebiewska, A., Buder, T., Nazarov, P. V., Muller, A., Poovathingal, S., Brons, N. H. C., Leite, S., Sauvageot, N., Sarkisjan, D., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09853-z · Cited by 529
Batchelor, T. T., Duda, D. G., di Tomaso, E., Ancukiewicz, M., Plotkin, S. R., Gerstner, E., Eichler, A. F., Drappatz, J., Hochberg, F. H., Benner, T., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3988 · Cited by 520
Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
Pottier, C., Fresnais, M., Gilon, M., Jérusalem, G., Longuespée, R., & Sounni, N. E. (2020) · Cancers · doi:10.3390/cancers12030731 · Cited by 515
Glioblastoma stem cells: lessons from the tumor hierarchy in a lethal cancer
Gimple, R. C., Bhargava, S., Dixit, D., & Rich, J. N. (2019) · Genes & Development · doi:10.1101/gad.324301.119 · Cited by 514
Leber, K. A., Berglöff, J., & Pendl, G. (1998) · Journal of Neurosurgery · doi:10.3171/jns.1998.88.1.0043 · Cited by 513
Hypoxia and Radiation Therapy: Past History, Ongoing Research, and Future Promise
Rockwell, S., Dobrucki, I., Kim, E., Marrison, S., & Vu, V. (2009) · Current Molecular Medicine · doi:10.2174/156652409788167087 · Cited by 511
Sotelo, J., Briceño, E., & López-González, M. A. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-5-200603070-00008 · Cited by 505
Hu, Y.-L., DeLay, M., Jahangiri, A., Molinaro, A. M., Rose, S. D., Carbonell, W. S., & Aghi, M. K. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3831 · Cited by 483
Engineered Extracellular Vesicles for Cancer Therapy
Zhang, X., Zhang, H., Gu, J., Zhang, J., Shi, H., Qian, H., Wang, D., Xu, W., Pan, J., & Santos, H. A. (2021) · Advanced Materials · doi:10.1002/adma.202005709 · Cited by 428
Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma
Bielamowicz, K., Fousek, K., Byrd, T. T., Samaha, H., Mukherjee, M., Aware, N., Wu, M.-F., Orange, J. S., Sumazin, P., Man, T.-K., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/nox182 · Cited by 425
Walsh, J. C., Lebedev, A., Aten, E., Madsen, K., Marciano, L., & Kolb, H. C. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5378 · Cited by 420
Mahmoudi, K., Bouras, A., Bozec, D., Ivkov, R., & Hadjipanayis, C. (2018) · International Journal of Hyperthermia · doi:10.1080/02656736.2018.1430867 · Cited by 414
Lombardi, G., De Salvo, G. L., Brandes, A. A., Eoli, M., Rudà, R., Faedi, M., Lolli, I., Pace, A., Daniele, B., Pasqualetti, F., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30675-2 · Cited by 397
Nanocarrier-based drug combination therapy for glioblastoma
Zhao, M., van Straten, D., Broekman, M. L. D., Préat, V., & Schiffelers, R. M. (2020) · Theranostics · doi:10.7150/thno.38147 · Cited by 373
Brain shift in neuronavigation of brain tumors: A review
Gerard, I. J., Kersten-Oertel, M., Petrecca, K., Sirhan, D., Hall, J. A., & Collins, D. L. (2017) · Medical Image Analysis · doi:10.1016/j.media.2016.08.007 · Cited by 324
Glioblastoma Multiforme: An Overview of Emerging Therapeutic Targets
Taylor, O. G., Brzozowski, J. S., & Skelding, K. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00963 · Cited by 322
The Role of Hypoxia in Glioblastoma Invasion
Monteiro, A., Hill, R., Pilkington, G., & Madureira, P. (2017) · Cells · doi:10.3390/cells6040045 · Cited by 321
Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives
Szopa, W., Burley, T. A., Kramer-Marek, G., & Kaspera, W. (2017) · BioMed Research International · doi:10.1155/2017/8013575 · Cited by 320
Current FDA-Approved Therapies for High-Grade Malignant Gliomas
Fisher, J. P., & Adamson, D. C. (2021) · Biomedicines · doi:10.3390/biomedicines9030324 · Cited by 316
Juillerat-Jeanneret, L. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.09.005 · Cited by 314
Chemoresistance of glioblastoma cancer stem cells - much more complex than expected
Beier, D., Schulz, J. B., & Beier, C. P. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-128 · Cited by 312
Immunostimulant hydrogel for the inhibition of malignant glioma relapse post-resection
Zhang, J., Chen, C., Li, A., Jing, W., Sun, P., Huang, X., Liu, Y., Zhang, S., Du, W., Zhang, R., et al. (2021) · Nature Nanotechnology · doi:10.1038/s41565-020-00843-7 · Cited by 305
Gliomas and the vascular fragility of the blood brain barrier
Dubois, L. G., Campanati, L., Righy, C., D’Andrea-Meira, I., Spohr, T. C. L. D. S. E., Porto-Carreiro, I., Pereira, C. M., Balça-Silva, J., Kahn, S. A., DosSantos, M. F., et al. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00418 · Cited by 303
The role of exosomes and miRNAs in drug‐resistance of cancer cells
Bach, D., Hong, J., Park, H. J., & Lee, S. K. (2017) · International Journal of Cancer · doi:10.1002/ijc.30669 · Cited by 296
Intratumoral heterogeneity in glioblastoma: don't forget the peritumoral brain zone
Lemée, J.-M., Clavreul, A., & Menei, P. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov119 · Cited by 295
Sampson, J. H., Choi, B. D., Sanchez-Perez, L., Suryadevara, C. M., Snyder, D. J., Flores, C. T., Schmittling, R. J., Nair, S. K., Reap, E. A., Norberg, P. K., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0709 · Cited by 291
Abdelwahab, M. G., Fenton, K. E., Preul, M. C., Rho, J. M., Lynch, A., Stafford, P., & Scheck, A. C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036197 · Cited by 288
ERGO: A pilot study of ketogenic diet in recurrent glioblastoma
RIEGER, J., BÄHR, O., MAURER, G. D., HATTINGEN, E., FRANZ, K., BRUCKER, D., WALENTA, S., KÄMMERER, U., COY, J. F., WELLER, M., et al. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2382 · Cited by 287
Oberoi, R. K., Parrish, K. E., Sio, T. T., Mittapalli, R. K., Elmquist, W. F., & Sarkaria, J. N. (2016) · Neuro-Oncology · doi:10.1093/neuonc/nov164 · Cited by 280
Jiang, X., Xin, H., Ren, Q., Gu, J., Zhu, L., Du, F., Feng, C., Xie, Y., Sha, X., & Fang, X. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.09.094 · Cited by 270
Nayak, L., Molinaro, A. M., Peters, K., Clarke, J. L., Jordan, J. T., de Groot, J., Nghiemphu, L., Kaley, T., Colman, H., McCluskey, C., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2500 · Cited by 265
Strategic design of extracellular vesicle drug delivery systems
Armstrong, J. P. K., & Stevens, M. M. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.06.017 · Cited by 257
Zhao, H.-F., Wang, J., Shao, W., Wu, C.-P., Chen, Z.-P., To, S.-S. T., & Li, W.-P. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0670-3 · Cited by 251
Cabrera, A. R., Kirkpatrick, J. P., Fiveash, J. B., Shih, H. A., Koay, E. J., Lutz, S., Petit, J., Chao, S. T., Brown, P. D., Vogelbaum, M., et al. (2016) · Practical Radiation Oncology · doi:10.1016/j.prro.2016.03.007 · Cited by 246
Chen, C., Duan, Z., Yuan, Y., Li, R., Pang, L., Liang, J., Xu, X., & Wang, J. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b15831 · Cited by 239
The Diagnosis and Treatment of Pseudoprogression, Radiation Necrosis and Brain Tumor Recurrence
Parvez, K., Parvez, A., & Zadeh, G. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms150711832 · Cited by 229
Targeting energy metabolism in brain cancer: review and hypothesis
Seyfried, T. N., & Mukherjee, P. (2005) · Nutrition & Metabolism · doi:10.1186/1743-7075-2-30 · Cited by 224
(2017) · Codon Publications eBooks · doi:10.15586/codon.glioblastoma.2017 · Cited by 220
Pafundi, D. H., Laack, N. N., Youland, R. S., Parney, I. F., Lowe, V. J., Giannini, C., Kemp, B. J., Grams, M. P., Morris, J. M., Hoover, J. M., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not002 · Cited by 218
Chlorotoxin-directed CAR T cells for specific and effective targeting of glioblastoma
Wang, D., Starr, R., Chang, W.-C., Aguilar, B., Alizadeh, D., Wright, S. L., Yang, X., Brito, A., Sarkissian, A., Ostberg, J. R., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw2672 · Cited by 215
The role of bevacizumab in the treatment of glioblastoma
Diaz, R. J., Ali, S., Qadir, M. G., De La Fuente, M. I., Ivan, M. E., & Komotar, R. J. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2477-x · Cited by 212
Intraoperative compensation for brain shift
Nimsky, C., Ganslandt, O., Hastreiter, P., et al. (2001) · Surgical Neurology · doi:10.1016/s0090-3019(01)00628-0 · Cited by 211
CD70, a novel target of CAR T-cell therapy for gliomas
Jin, L., Ge, H., Long, Y., Yang, C., Chang, Y. (., Mu, L., Sayour, E. J., De Leon, G., Wang, Q. J., Yang, J. C., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/nox116 · Cited by 211
Diaz, R. J., Dios, R. R., Hattab, E. M., Burrell, K., Rakopoulos, P., Sabha, N., Hawkins, C., Zadeh, G., Rutka, J. T., & Cohen-Gadol, A. A. (2015) · Journal of Neurosurgery · doi:10.3171/2015.2.jns132507 · Cited by 205
Krauze, A. V., Myrehaug, S. D., Chang, M. G., Holdford, D. J., Smith, S., Shih, J., Tofilon, P. J., Fine, H. A., & Camphausen, K. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2015.04.038 · Cited by 204
Aasland, D., Götzinger, L., Hauck, L., Berte, N., Meyer, J., Effenberger, M., Schneider, S., Reuber, E. E., Roos, W. P., Tomicic, M. T., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-1733 · Cited by 202
Nano-, micro-, and macroscale drug delivery systems for cancer immunotherapy
Huang, P., Wang, X., Liang, X., Yang, J., Zhang, C., Kong, D., & Wang, W. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.12.028 · Cited by 198
Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response
Baeuerle, P. A., Ding, J., Patel, E., Thorausch, N., Horton, H., Gierut, J., Scarfo, I., Choudhary, R., Kiner, O., Krishnamurthy, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10097-0 · Cited by 198
Sonoda, H., Morimoto, H., Yoden, E., Koshimura, Y., Kinoshita, M., Golovina, G., Takagi, H., Yamamoto, R., Minami, K., Mizoguchi, A., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.02.032 · Cited by 197
Glioblastoma cells release factors that disrupt blood-brain barrier features
Schneider, S. W., Ludwig, T., Tatenhorst, L., Braune, S., Oberleithner, H., Senner, V., & Paulus, W. (2004) · Acta Neuropathologica · doi:10.1007/s00401-003-0810-2 · Cited by 191
DNA repair mechanisms and their clinical impact in glioblastoma
Erasimus, H., Gobin, M., Niclou, S., & Van Dyck, E. (2016) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2016.05.005 · Cited by 188
Borghaei, H., Smith, M. R., & Campbell, K. S. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.09.067 · Cited by 183
Lu-Emerson, C., Duda, D. G., Emblem, K. E., Taylor, J. W., Gerstner, E. R., Loeffler, J. S., Batchelor, T. T., & Jain, R. K. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.9575 · Cited by 179
Bell-McGuinn, K. M., Matthews, C. M., Ho, S. N., Barve, M., Gilbert, L., Penson, R. T., Lengyel, E., Palaparthy, R., Gilder, K., Vassos, A., et al. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.12.362 · Cited by 179
Oszvald, Á., Güresir, E., Setzer, M., Vatter, H., Senft, C., Seifert, V., & Franz, K. (2012) · Journal of Neurosurgery · doi:10.3171/2011.8.jns102114 · Cited by 175
Intraoperative imaging technology to maximise extent of resection for glioma
Jenkinson, M. D., Barone, D. G., Bryant, A., Vale, L. D., Bulbeck, H., Lawrie, T. A., Hart, M. G., & Watts, C. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012788.pub2 · Cited by 174
Evolution of implantable and insertable drug delivery systems
Kleiner, L. W., Wright, J. C., & Wang, Y. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.02.006 · Cited by 173
Repair, Reuse, Recycle: The Expanding Role of Autophagy in Genome Maintenance
Hewitt, G., & Korolchuk, V. I. (2017) · Trends in Cell Biology · doi:10.1016/j.tcb.2016.11.011 · Cited by 172
Current Immunotherapies for Glioblastoma Multiforme
Huang, B., Li, X., Li, Y., Zhang, J., Zong, Z., & Zhang, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.603911 · Cited by 170
Self-citationSmall molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies
Hamer, P. C. D. W. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop068 · Cited by 166
Personalized treatment strategies in glioblastoma: MGMT promoter methylation status
Thon, N., Kreth, S., & Kreth, F. W. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s50208 · Cited by 166
Hsu, J., Chu, S., Liao, C.-C., Wang, C., Wang, Y.-S., Lai, M., Wang, H.-C., Huang, H., & Tsai, M.-H. (2021) · Cancers · doi:10.3390/cancers13020195 · Cited by 166
Vasconcelos, M. H., Caires, H. R., Ābols, A., Xavier, C. P. R., & Linē, A. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100647 · Cited by 164
Chryplewicz, A., Scotton, J., Tichet, M., Zomer, A., Shchors, K., Joyce, J. A., Homicskó, K., & Hanahan, D. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.08.014 · Cited by 163
Extracellular Vesicles in Glioblastoma Tumor Microenvironment
Yekula, A., Yekula, A., Muralidharan, K., Kang, K. M., Carter, B. S., & Balaj, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03137 · Cited by 162
Anti-angiogenic therapy for high-grade glioma
Ameratunga, M., Pavlakis, N., Wheeler, H., Grant, R., Simes, J., & Khasraw, M. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008218.pub4 · Cited by 159
Zhang, F., Xu, C., & Liu, C. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s79592 · Cited by 159
Clinical perspectives of PARP inhibitors
Graziani, G., & Szabó, C. (2005) · Pharmacological Research · doi:10.1016/j.phrs.2005.02.013 · Cited by 157
Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma
Lukas, R. V., Rodon, J. A., Becker, K. P., Wong, E. T., Shih, K. C., Touat, M., Fassò, M., Osborne, S., Molinero, L. L., O'Hear, C. E., et al. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2955-9 · Cited by 154
Magnetic nanoparticles: an emerging technology for malignant brain tumor imaging and therapy
Wankhede, M., Bouras, A., Kaluzová, M., & Hadjipanayis, C. G. (2012) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.12.1 · Cited by 153
DNA repair in personalized brain cancer therapy with temozolomide and nitrosoureas
Kaina, B., & Christmann, M. (2019) · DNA repair · doi:10.1016/j.dnarep.2019.04.007 · Cited by 149
Cabrini, G., Fabbri, E., Nigro, C. L., Dechecchi, M. C., & Gambari, R. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3026 · Cited by 146
Kolenda, J., Jensen, S. S., Aaberg-Jessen, C., Christensen, K., Andersen, C., Brünner, N., & Kristensen, B. W. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0357-8 · Cited by 144
The role of cancer stem cells in glioblastoma
Sundar, S. J., Hsieh, J. K., Manjila, S. V., Lathia, J. D., & Sloan, A. E. (2014) · Neurosurgical FOCUS · doi:10.3171/2014.9.focus14494 · Cited by 144
Zheng, Z., Zhang, J., Jiang, J., He, Y., Zhang, W., Mo, X., Kang, X., Xu, Q., Wang, B., & Huang, Y. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000207 · Cited by 144
Quader, S., Liu, X., Chen, Y., Mi, P., Chida, T., Ishii, T., Miura, Y., Nishiyama, N., Cabral, H., & Kataoka, K. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.04.033 · Cited by 143
Standards of care and novel approaches in the management of glioblastoma multiforme
Hottinger, A. F., Stupp, R., & Homicskó, K. (2014) · 癌症:英文版 · doi:10.5732/cjc.013.10207 · Cited by 141
Strategies to overcome/penetrate the BBB for systemic nanoparticle delivery to the brain/brain tumor
Liu, H., & Xu, P. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114619 · Cited by 141
Do Steroid Hormones Play a Role in the Etiology of Glioma?
Kabat, G. C., Etgen, A. M., & Rohan, T. E. (2010) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-0658 · Cited by 140
O6-Methylguanine-DNA methyltransferase inactivation and chemotherapy
Verbeek, B., Southgate, T. D., Gilham, D. E., & Margison, G. P. (2008) · British Medical Bulletin · doi:10.1093/bmb/ldm036 · Cited by 138
Uribe, D., Torres, Á., Rocha, J. D., Niechi, I., Oyarzun, C. E., Sobrevía, L., Martín, R. S., & Quezada, C. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.01.009 · Cited by 135
Immunocytokines are a promising immunotherapeutic approach against glioblastoma
Weiss, T., Puca, E., Silginer, M., Hemmerle, T., Pazahr, S., Bink, A., Weller, M., Neri, D., & Roth, P. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abb2311 · Cited by 133
Therapeutic Nanomedicine for Brain Cancer
Tzeng, S. Y., & Green, J. J. (2013) · Therapeutic Delivery · doi:10.4155/tde.13.38 · Cited by 130
Extracellular vesicle communication pathways as regulatory targets of oncogenic transformation
Choi, D., Lee, T. H., Spinelli, C., Chennakrishnaiah, S., D’Asti, E., & Rak, J. W. (2017) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2017.01.003 · Cited by 129
Li, T., Li, K., Zhang, Q., Wang, C., Yue, Y., Chen, Z., Yuan, S.-J., Liu, X., Wen, Y., Han, M. H., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.07.035 · Cited by 127
Klement, R. J., & Champ, C. E. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-014-9495-3 · Cited by 125
Targeted therapies: how personal should we go?
Martini, M., Vecchione, L., Siena, S., Tejpar, S., & Bardelli, A. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.164 · Cited by 124
The treatment of Glioblastoma Xenografts by surfactant conjugated dendritic nanoconjugates
Gajbhiye, V., & Jain, N. K. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.04.057 · Cited by 120
Advances and perspectives of PARP inhibitors
Yi, M., Dong, B., Qin, S., Chu, Q., Wu, K., & Luo, S. (2019) · Experimental Hematology & Oncology · doi:10.1186/s40164-019-0154-9 · Cited by 117
New trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapies
Westover, D., & Li, F. (2015) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-015-0275-x · Cited by 116
Ishihara, H., Kubota, H., Lindberg, R. L. P., Leppert, D., Gloor, S. M., Errede, M., Virgintino, D., Fontana, A., Yonekawa, Y., & Frei, K. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31816fd622 · Cited by 114
Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End
Datsi, A., & Sorg, R. V. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.770390 · Cited by 114
Zhao, Y., Li, Y., Zhao, J., Song, J., & Zhao, Y. (2016) · Reviews in the Neurosciences · doi:10.1515/revneuro-2015-0069 · Cited by 110
Xu, M., Zhang, C. Y., Wu, J., Zhou, H., Bai, R., Shen, Z., Deng, F., Liu, Y., & Liu, J. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b13059 · Cited by 110
Targeting mTOR in Glioblastoma: Rationale and Preclinical/Clinical Evidence
Mecca, C., Giambanco, I., Donato, R., & Arcuri, C. (2018) · Disease Markers · doi:10.1155/2018/9230479 · Cited by 105
Spinazzi, E. F., Argenziano, M., Upadhyayula, P. S., Banu, M. A., Neira, J. A., Higgins, D. M. O., Wu, P. B., Pereira, B., Mahajan, A., Humala, N., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00599-x · Cited by 104
Shirvalilou, S., Khoei, S., Khoee, S., Raoufi, N. J., Karimi, M. R., & Shakeri‐Zadeh, A. (2018) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2018.08.027 · Cited by 102
Nano-Enhanced Cancer Immunotherapy: Immunology Encounters Nanotechnology
Bockamp, E., Rosigkeit, S., Siegl, D., & Schuppan, D. (2020) · Cells · doi:10.3390/cells9092102 · Cited by 101
A basic review on systemic treatment options in WHO grade II-III gliomas
Mair, M. J., Geurts, M., van den Bent, M. J., & Berghoff, A. S. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102124 · Cited by 101
Fana, M., Gallien, J., Srinageshwar, B., Dunbar, G. L., & Rossignol, J. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s243155 · Cited by 100
Tapeinos, C., Marino, A., Battaglini, M., Migliorin, S., Brescia, R., Scarpellini, A., Fernández, C. D. J., Prato, M., Drago, F., & Ciofani, G. (2018) · Nanoscale · doi:10.1039/c8nr05520c · Cited by 99
The ketogenic diet for the treatment of malignant glioma
Woolf, E. C., & Scheck, A. C. (2014) · Journal of Lipid Research · doi:10.1194/jlr.r046797 · Cited by 98
Luo, Z., Jin, K., Pang, Q., Shen, S., Yan, Z., Jiang, T., Zhu, X., Yu, L., Pang, Z., & Jiang, X. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b10866 · Cited by 98
Immunotherapy for the Treatment of Glioblastoma
Thomas, A. A., Ernstoff, M. S., & Fadul, C. E. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e3182431a73 · Cited by 97
Liu, C., Liu, X., Wang, G., Hei, Y., Meng, S., Yang, L., Yuan, L., & Xie, Y. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s131367 · Cited by 94
van der Louw, E. J. T. M., Olieman, J. F., van den Bemt, P. M. L. A., Bromberg, J. E. C., Hoop, E. O., Neuteboom, R. F., Catsman‐Berrevoets, C. E., & Vincent, A. J. P. E. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919853958 · Cited by 94
Lu, Q., Dai, X., Zhang, P., Tan, X. H., Zhong, Y., Yao, C., Mei, S., Song, G., Zhang, Z., Peng, G., et al. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s157935 · Cited by 91
Shevtsov, M. A., Nikolaev, B. P., Marchenko, Y., Yakovleva, L. Y., Skvortsov, N., Mazur, A. S., Tolstoy, P. M., Ryzhov, V. A., & Multhoff, G. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s152461 · Cited by 90
Small molecule tyrosine kinase inhibitors in glioblastoma
Kim, G., & Ko, Y. T. (2020) · Archives of Pharmacal Research · doi:10.1007/s12272-020-01232-3 · Cited by 90
Brandes, A. A., Finocchiaro, G., Zagonel, V., Reni, M., Caserta, C., Fabi, A., Clavarezza, M., Maiello, E., Eoli, M., Lombardi, G., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now035 · Cited by 86
Li, T., Xu, Y., Li, K., Wang, C., Liu, X., Yue, Y., Chen, Z., Yuan, S.-J., Wen, Y., Zhang, Q., et al. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.01.020 · Cited by 83
Boado, R. J., & Pardridge, W. M. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b01166 · Cited by 82
Birocchi, F., Cusimano, M., Rossari, F., Beretta, S., Rancoita, P. M. V., Ranghetti, A., Colombo, S., Costa, B., Angel, P. E., Sanvito, F., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abl4106 · Cited by 81
Mechanisms of Drug Resistance in Cancer: The Role of Extracellular Vesicles
Samuel, P., Fabbri, M., & Carter, D. R. F. (2017) · PROTEOMICS · doi:10.1002/pmic.201600375 · Cited by 79
Delivery of siRNA based on engineered exosomes for glioblastoma therapy by targeting STAT3
Liang, S., Zuo, F.-F., Yin, B., & Ye, B. (2022) · Biomaterials Science · doi:10.1039/d1bm01723c · Cited by 75
High Expression of CD44 Predicts a Poor Prognosis in Glioblastomas
Si, D., Yin, F., Peng, J., & Zhang, G. (2020) · Cancer Management and Research · doi:10.2147/cmar.s233423 · Cited by 74
Recent development of contrast agents for magnetic resonance and multimodal imaging of glioblastoma
Zhuang, D., Zhang, H., Hu, G., & Guo, B. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01479-6 · Cited by 74
Temozolomide and Pituitary Tumors: Current Understanding, Unresolved Issues, and Future Directions
Syro, L. V., Rotondo, F., Camargo, M., Ortiz, L. D., Serna, C. A., & Kovács, K. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00318 · Cited by 73
PARP Inhibitors in Glioma: A Review of Therapeutic Opportunities
Sim, H., Galanis, E., & Khasraw, M. (2022) · Cancers · doi:10.3390/cancers14041003 · Cited by 71
Jiao, X., Yu, Y., Meng, J., He, M., Zhang, C. J., Geng, W., Ding, B., Wang, Z., & Ding, X. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.12.001 · Cited by 70
The Evolving Classification of Diffuse Gliomas: World Health Organization Updates for 2021
Perez, A., & Huse, J. T. (2021) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-021-01153-8 · Cited by 67
Integrin-αvβ3 as a Therapeutic Target in Glioblastoma: Back to the Future?
Echavidre, W., Picco, V., Faraggi, M., & Montemagno, C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14051053 · Cited by 66
Azagury, D. E., Dua, M. M., Barrese, J. C., Henderson, J. M., Buchs, N. C., Ris, F., Cloyd, J. M., Martinie, J. B., Razzaque, S., Nicolau, S., et al. (2015) · Current Problems in Surgery · doi:10.1067/j.cpsurg.2015.10.001 · Cited by 65
Wei, Y., Sun, Y., Wei, J., Qiu, X., Meng, F., Storm, G., & Zhong, Z. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.07.048 · Cited by 63
McCrea, H. J., Ivanidze, J., O’Connor, A., Hersh, E. H., Boockvar, J. A., Gobin, Y. P., Knopman, J., & Greenfield, J. P. (2021) · Journal of Neurosurgery Pediatrics · doi:10.3171/2021.3.peds20738 · Cited by 62
Gajewski, T. F., Sosman, J. A., Gerson, S. L., Liu, L., Dolan, M. E., Lin, S., & Vokes, E. E. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0060 · Cited by 61
Quader, S., Liu, X., Toh, K., Su, Y., Maity, A. R., Tao, A., Paraiso, W. K. D., Mochida, Y., Kinoh, H., Cabral, H., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120463 · Cited by 60
Stereotactic Radiosurgery for Glioblastoma
Redmond, K. J., & Mehta, M. P. (2015) · Cureus · doi:10.7759/cureus.413 · Cited by 58
Somani, S., Robb, G., Pickard, B. S., & Dufès, C. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.09.003 · Cited by 56
Maragkos, G. Α., Schüpper, A. J., Lakomkin, N., Sideras, P. A., Price, G. A., Baron, R. B., Hamilton, T., Haider, S. A., Lee, I. Y., Hadjipanayis, C. G., et al. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.644804 · Cited by 55
Aparicio-Blanco, J., Sanz-Arriazu, L., Lorenzoni, R., & Blanco‐Prieto, M. J. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119283 · Cited by 54
Lu, V. M., Jue, T. R., & McDonald, K. L. (2020) · Scientific Reports · doi:10.1038/s41598-020-75372-3 · Cited by 54
Stritzelberger, J., Distel, L. V., Buslei, R., Fietkau, R., & Putz, F. (2017) · Clinical & Translational Oncology · doi:10.1007/s12094-017-1743-x · Cited by 53
Hertler, C., Roth, P., Silginer, M., Florea, A., Lamszus, K., Frei, K., Deenen, R., Reifenberger, G., & Weller, M. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0772 · Cited by 51
Brar, H. K., Jose, J., Wu, Z., & Sharma, M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics15010059 · Cited by 51
Surgical approaches for the gliomas
Watts, C., & Sanai, N. (2016) · Handbook of clinical neurology · doi:10.1016/b978-0-12-802997-8.00004-9 · Cited by 50
Narita, Y. (2015) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s58289 · Cited by 49
Microfluidics in Malignant Glioma Research and Precision Medicine
Logun, M. T., Zhao, W., Mao, L., & Karumbaiah, L. (2018) · Advanced Biosystems · doi:10.1002/adbi.201700221 · Cited by 48
Automatic Intraoperative Correction of Brain Shift for Accurate Neuronavigation
Iversen, D. H., Wein, W., Lindseth, F., Unsgård, G., & Reinertsen, I. (2018) · World Neurosurgery · doi:10.1016/j.wneu.2018.09.012 · Cited by 46
Yang, Z., Wei, D., Dai, X., Stevens, M. F. G., Bradshaw, T. D., Luo, Y., & Zhang, J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00485 · Cited by 46
The Current State of Oncolytic Herpes Simplex Virus for Glioblastoma Treatment
Nguyen, H.-M., & Saha, D. (2021) · Oncolytic Virotherapy · doi:10.2147/ov.s268426 · Cited by 46
Bisht, P., Kumar, V. U., Pandey, R., Ravichandiran, V., & Kumar, N. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.939570 · Cited by 44
Janiszewska, J., Posadas, I., Játiva, P., Bugaj, M., Urbańczyk-Lipkowska, Z., & Ceña, V. (2016) · PLoS ONE · doi:10.1371/journal.pone.0165704 · Cited by 42
Heterogeneous reovirus susceptibility in human glioblastoma stem-like cell cultures
van den Hengel, S. K., Balvers, R. K., Dautzenberg, I. J. C., van den Wollenberg, D. J. M., Kloezeman, J. J., Lamfers, M. L. M., Sillivis-Smit, P. A. E., & Hoeben, R. C. (2013) · Cancer Gene Therapy · doi:10.1038/cgt.2013.47 · Cited by 39
Recent Advances on Glioblastoma Multiforme and Nano-drug Carriers: A Review
Liao, W., Fan, S., Zheng, Y., Liao, S., Xiong, Y., Li, Y., & Liu, J. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180514113136 · Cited by 38
Do, H. T., Bruelle, C., Pham, D. D., Jauhiainen, M., Eriksson, O., Korhonen, L. T., & Lindholm, D. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13397 · Cited by 37
Cytokine, Chemokine, and Co-Stimulatory Fusion Proteins for the Immunotherapy of Solid Tumors
Khawli, L. A., Hu, P., & Epstein, A. L. (2007) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-73259-4_13 · Cited by 36
Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter?
Aldaz, P., & Arozarena, I. (2021) · Cancers · doi:10.3390/cancers13225799 · Cited by 36
Bian, W., Khayal, I. S., Lupo, J., McGue, C., VandenBerg, S. R., Lamborn, K. R., Chang, S. M., Cha, S., & Nelson, S. J. (2009) · Translational Oncology · doi:10.1593/tlo.09178 · Cited by 35
Xu, K. W., Zhao, Z., Zhang, J., Xue, W., Tong, H., Liu, H., & Zhang, W. (2020) · Journal of Materials Chemistry B · doi:10.1039/c9tb02341k · Cited by 34
Epidemiology of Anthropometric Factors in Glioblastoma Multiforme—Literature Review
Simińska, D., Korbecki, J., Kojder, K., Kapczuk, P., Fabiańska, M., Gutowska, I., Machoy‐Mokrzyńska, A., Chlubek, D., & Baranowska‐Bosiacka, I. (2021) · Brain Sciences · doi:10.3390/brainsci11010116 · Cited by 34
Kong, L., Wu, J., Gao, J., Qiu, X., Yang, J., Hu, J., Hu, W., Mao, Y. Q., & Lu, J. J. (2020) · Cancer · doi:10.1002/cncr.32828 · Cited by 32
Lotocki, V., Yazdani, H., Zhang, Q., Gran, E. R., Nyrko, A., Maysinger, D., & Kakkar, A. K. (2020) · Macromolecular Bioscience · doi:10.1002/mabi.202000305 · Cited by 32
Forward Precision Medicine: Micelles for Active Targeting Driven by Peptides
Prencipe, F., Diaferia, C., Rossi, F., Ronga, L., & Tesauro, D. (2021) · Molecules · doi:10.3390/molecules26134049 · Cited by 32
Aptamer-decorated polydiacetylene micelles with improved targeting of cancer cells
Doerflinger, A., Quang, N. N., Gravel, E., Ducongè, F., & Doris, E. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.04.071 · Cited by 31
Romiplostim for temozolomide-induced thrombocytopenia in glioblastoma
Rhun, É. L., Devos, P., Houillier, C., Cartalat‐Carel, S., Chinot, O. L., Stefano, A. L. D., Lepage, C., Reyns, N., Dubois, F., & Weller, M. (2019) · Neurology · doi:10.1212/wnl.0000000000008440 · Cited by 27
Ge, Y., Zhong, Y., Ji, G., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0195703 · Cited by 26
Sönmez, C., Wölfer, J., Holling, M., Brokinkel, B., Stummer, W., Wiendl, H., Thomas, C., Schulte‐Mecklenbeck, A., & Grauer, O. M. (2022) · Scientific Reports · doi:10.1038/s41598-022-10680-4 · Cited by 24
Du, K., Xia, Q., Sun, J., & Feng, F. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c16962 · Cited by 23
Glioblastoma is ‘hot’ for personalized vaccines
Baratta, M. G. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0118-8 · Cited by 22
Glioblastoma multiforme: a glance at advanced therapies based on nanotechnology
Rezaei, V., Rabiee, A., & Khademi, F. (2020) · Journal of Chemotherapy · doi:10.1080/1120009x.2020.1713508 · Cited by 22
Germano, I. M., Ziu, M., Wen, P. Y., Ormond, D. R., & Olson, J. J. (2022) · Journal of Neuro-Oncology · doi:10.1007/s11060-021-03900-w · Cited by 22
Liu, P., Liu, G., Wang, G., Zhou, W., Sun, Y., Chen, W., Zeng, Q., Hong, J., Xie, Q., Ou, L., et al. (2020) · BioMed Research International · doi:10.1155/2020/4258989 · Cited by 19
Sowińska, M., Szeliga, M., Morawiak, M., Zabłocka, B., & Urbańczyk-Lipkowska, Z. (2022) · Biomolecules · doi:10.3390/biom12081116 · Cited by 18
Rivera-Caraballo, K., Nair, M., Lee, T. J., Kaur, B., & Yoo, J. Y. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.05.013 · Cited by 17
Montella, L., Sarno, F., Altucci, L., Cioffi, V., Sigona, L., Colandrea, S. D., SIMONE, S. D., Marinelli, A., Facchini, B. A., Vita, F. D., et al. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.703392 · Cited by 16
Cited by
Glioblastoma Therapy: Past, Present and Future
Obrador, E., Moreno-Murciano, P., Oriol-Caballo, M., López-Blanch, R., Pineda, B., Gutiérrez-Arroyo, J., Loras, A., Gonzalez-Bonet, L., Martinez-Cadenas, C., Estrela, J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052529 · Cited by 271
Targeting PP2A in cancer: an underrated option
Sarais, F., Krempien, F., Koehn, C., Brewing, L., Classen, C. F., Walter, M., & Shokraie, O. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03560-y · Cited by 8
Immunogenic cell death mediated TLR3/4-activated MSCs in U87 GBM cell line
Emami Meybodi, S. M., Moradi Moraddahande, F., & Dehghani Firoozabadi, A. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e29858 · Cited by 3
Metadata
- Authors
- Yalamarty, S. S. K., Filipczak, N., Li, X., Subhan, M. A., Parveen, F., Ataide, J. A., Rajmalani, B. A., & Torchilin, V. P.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2023-04-01
- Volume
- 15
- Issue
- 7
- Pages
- 2116
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W4362584099
- Cited by
- 293
- References
- 210
- FWCI
- 41.60
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.